# Revolution Medicines Drug Targets 'Undruggable' Cancer

> Revolution Medicines' Rasonque, the first drug to target RAS-addicted cancers, generated $198 million in five weeks.
- Title: Revolution Medicines Drug Targets 'Undruggable' Cancer
- Summary: Revolution Medicines' Rasonque, the first drug to target RAS-addicted cancers, generated $198 million in five weeks.
- Keywords: revolution medicines, rasonque, pancreatic cancer, phase 3 trials, oncology drugs, drug launch, The Motley Fool
- URL: https://shortify.news/The_Motley_Fool/revolution-medicines-drug-targets-undruggable-cancer
- Source: The Motley Fool — https://fool.com/investing/2026/11/20/revolution-medicines-drugged-a-target-scientists-called-undruggable-for-decades-buy-the-stock-hand-over-fist
- Author: Prosper Junior Bakiny
- Published: 2026-11-20T20:36:02+00:00
- Read time: 1 min
- Topics: revolution medicines, rasonque, pancreatic cancer, phase 3 trials, oncology drugs, drug launch, finance, money
## Rasonque Approval
Revolution Medicines earned approval for Rasonque, a medicine for pancreatic cancer targeting RAS-addicted cancers.
## Strong Launch
Rasonque generated $198 million in five weeks, marking the strongest oncology drug launch on record.
## Clinical Results
Rasonque led to a median overall survival of 13.2 months versus 6.7 months with chemotherapy in Phase 3 trials.
## RAS-Addicted Cancers
RAS-addicted cancers account for 20% to 30% of all human cancers, making Rasonque's target historically undruggable.
## Pipeline Progress
Revolution Medicines has eight Phase 3 clinical trials, including two investigational medicines, zoldonrasib and elironrasib.
## Market Reaction
Shares rose 100% this year after Rasonque's approval, but declined 29% since launch despite strong sales.
## Valuation Justification
The company's $34.8 billion market cap is justified by potential $3 billion in next year's revenue and 11.6x sales valuation.
## Key takeaway

Revolution Medicines' Rasonque achieved the strongest oncology drug launch in history with $198 million revenue in five weeks.

---

Summary: Shortify — https://shortify.news/The_Motley_Fool/revolution-medicines-drug-targets-undruggable-cancer
Reporting: The Motley Fool — https://fool.com/investing/2026/11/20/revolution-medicines-drugged-a-target-scientists-called-undruggable-for-decades-buy-the-stock-hand-over-fist

When you use this summary, link the Shortify URL for the summary and credit the reporting to its newsroom.